$FIGS

FIGS Inc (FIGS) Stock Up 5.3% but GF Value Says Overvalued -- GF

FIGS Inc (FIGS) shares rose 5.3% to $15.78 on October 9, 2026. GuruFocus' GF Value™ estimates the stock is overvalued by 103.1%, with an intrinsic value of $7.77. The company has a GF Score™ of 77/100, indicating above-average financial health. Insiders sold $12.7 million in shares over the past year, with no purchases. The P/E ratio is 48.9x, below its 5-year median of 72.1x.

Original reporting
Published Oct 9, 2026, 11:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 11, 2026, 5:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$FIGS
Bearish
high confidence
Mentioned
$FIGS
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$FIGSBearishLow
01

Why it matters

The overvaluation signal may prompt short‑term traders to consider downside positions.

02

Market read

Valuation overstatement and insider selling suggest near‑term risk for FIGS.

03

What to watch

Potential upcoming product launches or contract wins not covered in the article.

Relevance 4/10Novelty 2/10Timing: today

Background

GuruFocus provides a proprietary valuation model; the article is a valuation commentary rather than a corporate event.

Company-level read

Ticker impact

$FIGSBearishHigh confidence
Context

Article highlights that FIGS shares are 103% above GuruFocus intrinsic value and notes $12.7M of insider sales, suggesting overvaluation and potential downside.

Expected impact

likely downward pressure as investors reassess valuation

Evidence & confidence

The article provides a fresh valuation gap and insider sell data, which typically trigger sell‑offs.

Market effects

Limited; valuation concerns may affect other medical‑apparel peers.

US market only.

Low

Counterpoint

Some investors may view the high growth rating as a buying opportunity despite valuation.

Key entities

  • FIGS Inc.

    US‑listed medical apparel retailer

Related articles

$FIGSHighAI 9/10

FIGS (FIGS) Q2 2026 Earnings Call Transcript

FIGS, Inc. (FIGS) reported Q2 2026 net revenues of $196.6 million, up 28.8%, driven by higher order volume and record average order values. Scrubwear revenue rose 26.5% to $161.2 million. Gross margin was 75.2% and net income $28.4 million. The company raised FY2026 net revenue guidance to about 20% growth and EBITDA margin to 14.8% to 15.0%.

$FIGSMedAI 8/10

FIGS Stock Soars After Earnings Beat And Upgraded Outlook

FIGS Inc. (NYSE: FIGS) shares rose about 28.7% in a week after a Q2 earnings beat and an upgraded FY26 outlook, according to the article. Q2 results included EPS $0.15 vs $0.07 and revenue up 29% to $196.6M, with gross margin 66.6% and adjusted EBITDA margin 18.6%. FY26 guidance was raised to about 20% revenue growth and 14.8% to 15% EBITDA margin.

$FIGSHighAI 9/10

FIGS Q2 Earnings Call Highlights

FIGS (NYSE:FIGS) reported Q2 results and an earnings call update. International revenue rose 67% to $37.9M and U.S. revenue grew 22% to $158.7M. Gross margin increased to 75.2% with a $15.4M tariff refund benefit. Net income was $28.4M, or $0.15/share. FIGS raised FY2026 revenue growth to ~20% and operating margin to ~10.8%, and repurchased about $24M of shares.

$FIGSHighAI 9/10

FIGS Stock Jumped 27% on Its Q2 Beat. The Raised Guide Did the Real Work.

FIGS (FIGS) shares rose about 27% on Aug. 7 after Q2 results beat estimates and management raised full-year guidance. Q2 revenue was $196.6M (+29% YoY) and EPS was $0.15 vs $0.07 consensus. Gross margin hit 75.2% but included a one-time tariff refund; core margin improved. Full-year growth guidance lifted to ~20% from 14% to 16%, plus a $100M buyback authorization.